Maintenance of breast size reduction after mastoplasty and switch to a protease inhibitor-sparing regimen in an HIV-positive woman with highly active antiretroviral therapy-associated massive breast enlargement.
Fat distribution disorders are among the most frequent side effects of antiretroviral treatment. The pathophysiologic mechanism(s) for these events remains unclear, and a casual link to a specific drug or class of drugs is uncertain. The physical changes associated with the lipodystrophy syndrome can be divided into three major types: lipoatrophy or fat wasting; lipohypertrophy or fat accumulation; and mixed forms with atrophy and hypertrophy coexisting in different body regions. Fat accumulation can occur in one or more of several areas including dorsal-cervical and abdominal regions and breasts. Withdrawal of antiretroviral therapy does not seem to influence the stabilized lesions significantly, and no one of the therapeutic strategies adopted so far was capable to achieve substantial improvements. Here we describe the successful and lasting treatment of a massive and movement/posture-hampering breast hypertrophy with reductive mastoplasty.
Institute of Infectious Diseases and Tropical Medicine, University of Milan, Milan, Italy.
Cristina
C
Gervasoni
Anna Lisa
AL
Ridolfo
Luca
L
Rovati
Mauro
M
Vaccarezza
Luca
L
Carsana
Massimo
M
Galli
Luca
L
Cassana
D000273:Adipose Tissue / Q000187:drug effects / Q000254:growth & development / Q000601:surgery; D000328:Adult; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D001940:Breast / Q000473:pathology*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D006984:Hypertrophy / Q000139:chemically induced / Q000601:surgery; D016462:Mammaplasty